Animals and Transgenesis Peter Paras, Jr.. 2 Overview Introduction — Definitions Types of Transgenic Animals — How they are made Examination of Transgenic.

Slides:



Advertisements
Similar presentations
Enablement and Written Description Issues in Utility Plant Applications Gary Benzion, Ph.D. Acting Supervisory Patent Examiner AU 1638.
Advertisements

Patenting Antisense Oligonucleotides and Methods
Proteomics Examination Yvonne (Bonnie) Eyler Technology Center 1600 Art Unit 1646 (703)
Utility and Written Description Steve Kunin Deputy Commissioner for Patent Examination Policy Esther Kepplinger Deputy Commissioner for Patent Operations.
October 2007KSR Training1 TC 3700 KSR Sample Rejection.
1 Homology Language Brian R. Stanton Quality Assurance Specialist Technology Center 1600 U.S. Patent and Trademark Office (703)
1 35 U.S.C. § 112, first paragraph and the Wands Analysis Remy Yucel, SPE 1636 (571)
1 Rule 132 Declarations and Unexpected Results Richard E. Schafer Administrative Patent Judge Board of Patent Appeals and Interferences.
1 35 USC 112, 1 st paragraph enablement Enablement Practice in TC 1600 Deborah Reynolds, SPE
35 U.S.C. 112, Sixth Paragraph MPEP 2181 – 2186 Jean Witz Quality Assurance Specialist Technology Center 1600.
Gene Therapy: Overcoming Enablement Rejections Karen M. Hauda Supervisory Patent Examiner Art Unit 1632 (703)
Proteomics and “Orphan” Receptors Yvonne (Bonnie) Eyler Technology Center 1600 Art Unit 1646 (703)
“REACH-THROUGH CLAIMS”
1 Biotechnology Partnership Meeting April 17, 2001 James Martinell Senior Level Examiner Technology Center 1600.
Determination of Obviousness Practice Under the Genus-Species Guidelines and In re Ochiai; In re Brouwer Sreeni Padmanabhan & James Wilson Supervisory.
1 Single Nucleotide Polymorphisms (SNP) Gary Jones SPE, Technology Center 1600 (703)
Patent Processing – Examination Issues Patent, Trademark, and Copyright - Law and Policy 5-8 November 2007 Amman, Jordan Global Intellectual Property Academy.
Restriction Practice for Genus Claims Species Claims Linking Claims and Markush Claims Julie Burke QAS/PM TC1600.
EVALUATING SUBJECT MATTER ELIGIBILITY UNDER 35 U. S. C
Determining Obviousness under 35 USC 103 in view of KSR International Co. v. Teleflex TC3600 Business Methods January 2008.
Biotechnology/Chemical/Pharmaceutical Customer Partnership Topic: Biotechnology/Chemical/Pharmaceutical Customer Partnership Topic: Examining Issues When.
2 March, 2005 Chapter 12 Mutational dissection Normal gene Altered gene with altered phenotype mutagenesis.
Intellectual Property Boston College Law School March 3, 2008 Patent - Nonobviousness.
Patent Overview by Jeff Woller. Why have Patents? Patents make some people rich – but, does that seem like something the government should protect? Do.
Issues in Patenting Proteins Jon P Weber, SPE 1657.
Intellectual Property Boston College Law School February 16, 2009 Patent – Novelty.
Patent Applications Overlapping the Biotechnology and Mechanical Arts THOMAS BARRETT
Lauren MacLanahan Office of Technology Licensing GTRC.
Examination Issues: Immunology Yvonne (Bonnie) Eyler Quality Assurance Specialist Technology Center 1600 USPTO (571)
1 Unity of Invention: Biotech Examples TC1600 Special Program Examiner Julie Burke (571)
1 Intellectual Property Protection for Plants in the United States Anne Marie Grünberg Supervisory Patent Examiner Art Units 1661 and 1638.
Stem Cells Peter Paras, Jr.. 2 Overview Introduction — Definitions Types of Stem Cells — Origin Examination of Stem Cell Claims — Statutes — Sample Claims.
Utility Requirement in Japan Makoto Ono, Ph.D. Anderson, Mori & Tomotsune Website:
1 ANTICIPATION BY INHERENCY IN PRIOR ART James O. Wilson Supervisory Patent Examiner Technology Center 1600 USPTO (571)
Broadening the Scope of the Claims in Gene Therapy Applications Deborah Reynolds Detailee, TCPS
Unit 4 Vocabulary Review. Nucleic Acids Organic molecules that serve as the blueprint for proteins and, through the action of proteins, for all cellular.
1 Kathleen Kerr Bragdon Quality Assurance Specialist Technology Center 1600 Kathleen Kerr Bragdon Quality Assurance Specialist Technology Center 1600 Patents.
Routine Optimization Jean Witz, tQAS, TC
Patenting Interfering RNA
U.S. Patent and Trademark Office Technology Center 1600 Michael P. Woodward Unity of Invention: Biotech Examples.
Overcoming Prior Art References Non-Enabling Prior Art References Gary Kunz SPE Art Unit 1616.
Josiah Hernandez Patentability Requirements. Useful Having utilitarian or commercial value Novel No one else has done it before If someone has done it.
1 Written Description Analysis and Capon v. Eshhar Jeffrey Siew Supervisory Patent Examiner AU 1645 USPTO (571)
Patentability of Reach-Through Claims Brian R. Stanton Practice Specialist Technology Center 1600 (703)
Patentability Considerations in the 3-D Structure Arts Patentability Considerations in the 3-D Structure Arts Michael P. Woodward Supervisory Patent Examiner.
Genetic Engineering Application of techniques of molecular cloning and transformation.
Trilateral Project WM4 Report on comparative study on Examination Practice Relating to Single Nucleotide Polymorphisms (SNPs) and Haplotypes. Linda S.
1 Demystifying the Examination of Stem Cell-Related Inventions Remy Yucel, Ph.D. Supervisory Patent Examiner Technology Center 1600 United States Patent.
Examining Claims for Compliance with 35 U.S.C. 112(a): Part II – Enablement Focus on Electrical/Mechanical and Computer/Software-related Claims August.
UNITED STATES PATENT AND TRADEMARK OFFICE
Josiah Hernandez What can be Patented. What can be patented A patent is granted to anyone who “invents or discovers any new and useful process, machine,
Vector Claims in Gene Therapy Applications: In vivo vs. In vitro Utilities Deborah Reynolds SPE GAU
Patenting Interfering RNA John LeGuyader – SPE Art Unit 1635 (571)
How to Claim your Biotech- Based Invention Deborah Reynolds Detailee, TCPS
1 Enablement Issues in Pharmaceutical Claims Joseph K. M c Kane Supervisory Patent Examiner Art Unit Ardin Marschel Supervisory Patent.
Examination Practice in Applications Presenting “Reach-Through Claims” George Elliott Practice Specialist Technology Center 1600
Patentable Subject Matter Donald M. Cameron. 2 Patents: The Bargain Public: gets use of invention after patent expires Inventor/Owner: gets limited monopoly.
© 2008 International Intellectual Property June 16, 2009 Class 2 Introduction to Patents.
Double Patenting Deborah Reynolds SPE Art Unit 1632 Detailee, TC1600 Practice Specialist
Genes and Development Gene theory: controversy whether the material of inheritance was in the nucleus or cytoplasm. Do all cells share the same genome?
1 Utility Guidelines, Homology Claims and Anti-Sense Molecule Claims Drew Hissong, Ph.D. dhissong*sughrue.com Sughrue Mion, PLLC
Class 24: Finish Remedies, then Subject Matter Patent Law Spring 2007 Professor Petherbridge.
LYDON - TERMINAL DISCLAIMERS1 Terminal Disclaimer (TD) A Terminal Disclaimer states that the patent –will expire on the same date as a related.
Ram R. Shukla, Ph.D. SPE AU 1632 & 1634 Technology Center
Global Innovation Management Workout on Writing a Patent
Dr. Peter John M.Phil, PhD Atta-ur-Rahman School of Applied Biosciences (ASAB) National University of Sciences & Technology (NUST)
Stem Cells Peter Paras, Jr.
A tutorial and update on patentable subject matter
Examination Practice in Applications Presenting “Reach-Through Claims”
Examination Issues: Immunology
Presentation transcript:

Animals and Transgenesis Peter Paras, Jr.

2 Overview Introduction — Definitions Types of Transgenic Animals — How they are made Examination of Transgenic Claims — Statutes — Sample Claims

3 Introduction: Definitions Transgene — A foreign gene that has been incorporated into the genome of an organism. Random Integration Homologous Recombination Gain or Loss of Function Transgenic Animal — An organism that contains a transgene that is passed down to its descendents.

4 Introduction: Definitions Phenotype — Any observable characteristic or trait of an organism: such as its morphology, development, biochemical or physiological properties, or behavior. Results from expression (or lack thereof) of an organism's genes as well as the influence of environmental factors and possible interactions between the two. — Correlates to uses of transgenic animals

5 Types of Animals Transgene and Method of Introduction=Type of transgenic Animal Made Overexpressers — Random Integration — Gain of Function — Expression Promoter — Phenotype

6 Types of Animals (cont.) Overexpressers (cont.) — Limitations Transgene Expression Level – High/Low Expressers – Site of Integration – Copy Number Unpredictability of Phenotypes – Different Species – Disease – Gene Function

7 Types of Animals (cont.) Knockouts/Knockins — Homologous Recombination Targeted Insertion – Loss of Function – Targeted Gene is Disrupted – Lacks Expression – Gain of Function Phenotype Correlates to Loss or Gain of Function – Homozygous — Embryonic Stem (ES) Cells

8 Types of Animals (cont.) Knockouts/Knockins (cont.) — Limitations Availability of ES cells – Germline Transmission Unpredictable Phenotype – Gene Function – Unknown – Phenotype May not Correlate with Function – Hybrid Genetic Background

9 Types of Animals (cont.) Nuclear Transfer Animals — Genetic Material from Donor Nucleus Somatic Cell Embryonic Stem Cell — Recipient Enucleated Ooycte — Genetically Modified Offspring – Fibroblast — Clones

10 Types of Animals (cont.) Nuclear Transfer Animals (cont.) — Limitations Methodology Limited to Non-Primate Mammals Cell Type of Transfected Donor Cells – Fibroblasts

11 Common Examination Issues in Animal Patents 35 USC 101 Utility Statutory Invention 35 USC 112, 1 st paragraph Enablement Written Description 35 USC 103-Obviousness 35 USC 102-Novelty

12 Examination Issues in Animal Patents-Utility Specific, Substantial, and Credible — Use must be based upon specific (particular) combination of elements Transgene + Animal + phenotype — General use such as snake food would not be considered substantial, unless invention is directed to enhanced animal feed — Credibility assessed from perspective of skill and knowledge in the art

13 Examination Issues in Animal Patents-Utility (cont.) Sample Claim: A transgenic mouse whose genome comprises a homozygous disruption in gene X, wherein gene X is not expressed and the mouse has a phenotype of running in circles.

14 Examination Issues in Animal Patents-Utility (cont.) Considerations: — What is known about Gene X? Art and Specification – Function? — Is there a correlation between the disclosed phenotype (running in circles) and a disease or Gene X function? Art and Specification — What are the disclosed utilities of the transgenic mouse? General or Specific?

15 Examination Issues in Animal Patents-Utility (cont.) Considerations (cont.) — Utility Guidelines Example 4-uncharacterized proteins – Gene X encodes an uncharacterized protein Example 11-animals with uncharacterized human genes – Correlation to Disease – Gene X has no apparent correlation to disease

16 Examination Issues in Animal Patents-Statutory Invention Section 101 of title 35, United States Code, provides: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

17 Examination Issues in Animal Patents-Statutory Invention (cont.) As the Supreme Court has recognized, Congress chose the expansive language of 35 U.S.C. 101 so as to include “anything under the sun that is made by man” as statutory subject matter. Diamond v. Chakrabarty, 447 U.S. 303, , 206 USPQ 193, 197 (1980). MPEP 2106

18 Examination Issues in Animal Patents-Statutory Invention (cont.) Is The Claimed Invention Statutory? — Product of Nature? — Hand of Man? — Humans? 1077 O.G. 24, April 21, 1987.

19 Examination Issues in Animal Patents-Statutory Invention (cont.) Sample Claim An animal comprising a mutation in gene Z.

20 Examination Issues in Animal Patents-Statutory Invention (cont.) Considerations — Product of Nature? Hand of Man Naturally Occurring Mutation in Gene Z — Prior Art Invention known — Does the Claim Embrace Humans?

21 Examination Issues in Animal Patents-Enablement How to “make” the animals — Random Integration-“Standard” zygote transduction Now considered relatively routine BUT, phenotype is often based upon a unique integration event and expression – Consider reproducibility and scope of claims — Homologous recombination Embryonic stem cell availability often questionable

22 Examination Issues in Animal Patents-Enablement (cont.) What is the “use” of the animal? — Is it based upon the phenotype? Consider claiming a scope of animal/phenotype that would be expected to have a “useful” property Is Transgene Expression Enough? – Reporter Molecules

23 Examination Issues in Animal Patents-Enablement (cont.) Consider Wands factors-MPEP (a) — Breadth of the Claims — Nature of the Invention — The state of the Prior Art — The Level of One of Ordinary Skill — The Level of Predictability in the Art — The Amount of Direction Provided by the Inventor — The Existence of Working Examples — The Quantity of Experimentation Needed to Make or Use the Invention Based on the Content of the Disclosure

24 Examination Issues in Animal Patents-Enablement (cont.) Sample Claim A transgenic non-human animal whose genome comprises a transgene operably linked to a promoter, wherein the animal exhibits brain cancer resulting from expression of the transgene.

25 Examination Issues in Animal Patents-Enablement (cont.) Considerations — Is the phenotype (brain cancer) predictable across animal species? Breadth of claims Working Examples State of Art Regarding Transgene Expression/Phenotypes – Transgene – Promoter Guidance/Teachings Provided by the Specification

26 Examination Issues in Animal Patents-Written Description Identify disclosed distinguishing characteristics as they relate to the scope and content of the claims — Genus of Nucleic Acid Molecules (Transgenes) Embraced by the Claims identify essential structural elements Identify species explicitly or implicitly disclosed reconcile with the level of skill in the art

27 Examination Issues in Animal Patents-Written Description (cont.) Sample Claim: A transgenic non-human animal whose genome comprises a disruption in an endogenous gene, wherein the endogenous gene is not expressed and the animal exhibits the ability to do back-flips.

28 Examination Issues in Animal Patents-Written Description (cont.) Considerations — Scope of the disrupted gene? Genus Species Definitions Structure/Function Written Description Guidelines –

29 Examination Issues in Animal Patents-35 USC 103 What’s in a Claim? — Broad limitation to animal comprising mutation or transgene? For “known” genes – “routine” to make transgenic or mutant — Specific Limitation to Phenotype? Is phenotype “expected”? Is phenotype required?

30 Examination Issues in Animal Patents-35 USC 103 (cont.) Sample Claim: A transgenic mouse whose genome comprises a transgene encoding a human qrt gene operably linked to a promoter, wherein expression of human qrt results in liver cancer.

31 Examination Issues in Animal Patents-35 USC 103 (cont.) Considerations — Routine to make a transgenic mouse? — What is Known About the qrt gene? Specification Art – Correlation to Liver Cancer? – Predictability of Liver Cancer Phenotype? – Known qrt mutation correlated with liver cancer in humans?

32 Examination Issues in Animal Patents-35 USC 102 What’s in a claim? — Broadest Reasonable Interpretation of Claimed Invention Consistent with the Teachings of the Specification Prior Art — Invention Known? — All Claimed Embodiments Taught? — Inherent Properties? Same transgene-different phenotype Claimed and prior art mice appear structurally the same

33 Examination Issues in Animal Patents-35 USC 102 (cont.) Where the claimed and prior art products are identical or substantially identical in structure or composition, or are produced by identical or substantially identical processes, a prima facie case of either anticipation or obviousness has been established. In re Best, 562 F.2d 1252, 1255, 195 USPQ 430, 433 (CCPA 1977). MPEP

34 Examination Issues in Animal Patents-35 USC 102 (cont.) [Therefore,] the prima facie case can be rebutted by evidence showing that the prior art products do not necessarily possess the characteristics of the claimed product. In re Best, 562 F.2d at 1255, 195 USPQ at 433.

35 Questions Thank You! Peter Paras, Jr Supervisory Patent Examiner Art Unit